Berenberg Bank Remains a Hold on GlaxoSmithKline (GSK)
Berenberg Bank analyst Kerry Holford reiterated a Hold rating on GlaxoSmithKline today and set a price target of p2,000.00.
Claim 30% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Holford is a 3-star analyst with an average return of 5.4% and a 55.00% success rate. Holford covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Pfizer, and Novo Nordisk.
In addition to Berenberg Bank, GlaxoSmithKline also received a Hold from Deutsche Bank ‘s Emmanuel Papadakis in a report issued on March 24. However, on the same day, TipRanks – Google reiterated a Buy rating on GlaxoSmithKline (LSE: GSK).
Based on GlaxoSmithKline’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of p8.62 billion and a net profit of p636 million. In comparison, last year the company earned a revenue of p8.12 billion and had a net profit of p414 million
Based on the recent corporate insider activity of 327 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GSK in relation to earlier this year.
Read More on GB:GSK:
Disclaimer & DisclosureReport an Issue
- GSK Continues Share Buyback, Lifts Treasury Holdings to 6.27% of Voting Rights
- GSK Reports Routine ADS Acquisition by U.S. President Martinez-Davis
- GSK Publishes 2026 AGM Notice and Details Hybrid Shareholder Meeting
- GSK Expands Share Buyback, Lifts Treasury Holdings to 6.26%
- GSK Expands Share Buyback, Lifts Treasury Holding to 6.25% of Voting Rights
